GlassScriptPhysician profile
Juan J Bayron
NPI 1932104015
$2,433.14
in general payments reported to CMS, 2019-2025
14 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $410 · 2021: $519 · 2022: $385 · 2023: $189 · 2024: $219 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $649.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $504.36 | 2019-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $449.95 | 2019-2023 | Janumet, Steglatro, Januvia |
| Janssen Pharmaceuticals, INC | $409.43 | 2019-2023 | Invokana, Xarelto |
| Pbg Puerto Rico LLC | $305.36 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $227.11 | 2020-2024 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $212.97 | 2021-2025 | Eliquis |
| Glaxosmithkline, LLC. | $80.46 | 2019-2020 | |
| Dexcom, INC. | $79.17 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $49.18 | 2024 | Cologuard Collection Kit |
| Pfizer INC. | $28.18 | 2023 | |
| Lilly USA, LLC | $25.00 | 2025 | Jardiance |
| Biotronik INC. | $24.48 | 2019 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $20.00 | 2022 | |
| Chiesi USA, INC. | $17.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Bayron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.